HC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock Price

REGENXBIO (NASDAQ:RGNX) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on RGNX. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Friday. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Trading Up 4.2 %

Shares of NASDAQ RGNX opened at $7.00 on Monday. REGENXBIO has a 1-year low of $5.62 and a 1-year high of $23.14. The company has a market cap of $346.82 million, a PE ratio of -1.39 and a beta of 1.35. The company has a 50-day moving average of $7.29 and a two-hundred day moving average of $8.97.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. As a group, equities research analysts forecast that REGENXBIO will post -4.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC grew its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. KLP Kapitalforvaltning AS acquired a new position in REGENXBIO during the fourth quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new position in REGENXBIO during the fourth quarter valued at approximately $79,000. Finally, Laurion Capital Management LP acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.